@prefix fhir: . @prefix owl: . @prefix rdfs: . @prefix xsd: . # - resource ------------------------------------------------------------------- a fhir:CodeSystem ; fhir:nodeRole fhir:treeRoot ; fhir:id [ fhir:v "ssf-2-leukemia-codesystem"] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "

Generated Narrative: CodeSystem ssf-2-leukemia-codesystem

This case-sensitive code system https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem defines the following codes:

CodeDisplay
000 正常
001 AML with RUNX1-RUNX1T1
002 AML with CBFB-MYH11
003 Acute promyelocytic leukemia with PML-RARA
004 AML with KMT2A-MLLT3
005 AML with DEK-NUP214
006 AML with GATA2, MECOM
007 AML(megakaryoblastic) with RBM15-MKL1
008 AML with mutated NPM1
009 AML with biallelic mutation of CEBPA
010 AML with mutated FLT3/ITD
011 AML with mutated FLT3/TKD
012 AML with MLL-PTD (partial tandem duplication)
013 AML with BCR-ABL1
021 B lymphoblastic leukemia/lymphoma with BCR-ABL1
022 B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged
023 B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1)
024 B-lymphoblastic leukemia/lymphoma with IGH/IL3
025 B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1)
041 Mixed phenotype acute leukemia with BCR-ABL1
042 Mixed-phenotype acute leukemia with KMT2A-rearranged
051 Chronic myelogenous leukemia BCR-ABL1 positive
052 JAK2 V617F mutation
053 Myeloid and lymphoid neoplasms with PDGFRA rearrangement
054 Myeloid and lymphoid neoplasms with PDGFRB rearrangement
055 Myeloid and lymphoid neoplasms with FGFR1 rearrangement
090 (1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常
091 同時有兩種(含)以上上述之分子檢驗異常
092 同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常
8XX Molecular study after chemotherapy or immunotherapy or target therapy
988 不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4)
998 有執行分子生物學檢查，但結果無法判斷
999 (1) 病歷未記載或不詳 (2) 未執行分子生物學檢查
" ] ; # fhir:url [ fhir:v "https://hapi.fhir.tw/fhir/CodeSystem/ssf-2-leukemia-codesystem"^^xsd:anyURI] ; # fhir:version [ fhir:v "0.1.1"] ; # fhir:name [ fhir:v "SSF2leukemiaCS"] ; # fhir:title [ fhir:v "SSF2 白血病-白血病分子生物學檢查的評估代碼系統"] ; # fhir:status [ fhir:v "active"] ; # fhir:experimental [ fhir:v "false"^^xsd:boolean] ; # fhir:date [ fhir:v "2024-08-01T15:33:47+08:00"^^xsd:dateTime] ; # fhir:publisher [ fhir:v "Kuo"] ; # fhir:contact ( [ fhir:name [ fhir:v "Kuo" ] ; fhir:telecom ( [ fhir:system [ fhir:v "url" ] ; fhir:value [ fhir:v "http://example.org/example-publisher" ] ] ) ] ) ; # fhir:description [ fhir:v "Assessment of molecular studies in leukemia Code System"] ; # fhir:caseSensitive [ fhir:v "true"^^xsd:boolean] ; # fhir:content [ fhir:v "complete"] ; # fhir:count [ fhir:v "33"^^xsd:nonNegativeInteger] ; # fhir:concept ( [ fhir:code [ fhir:v "000" ] ; fhir:display [ fhir:v "正常" ] ] [ fhir:code [ fhir:v "001" ] ; fhir:display [ fhir:v "AML with RUNX1-RUNX1T1" ] ] [ fhir:code [ fhir:v "002" ] ; fhir:display [ fhir:v "AML with CBFB-MYH11" ] ] [ fhir:code [ fhir:v "003" ] ; fhir:display [ fhir:v "Acute promyelocytic leukemia with PML-RARA" ] ] [ fhir:code [ fhir:v "004" ] ; fhir:display [ fhir:v "AML with KMT2A-MLLT3" ] ] [ fhir:code [ fhir:v "005" ] ; fhir:display [ fhir:v "AML with DEK-NUP214" ] ] [ fhir:code [ fhir:v "006" ] ; fhir:display [ fhir:v "AML with GATA2, MECOM" ] ] [ fhir:code [ fhir:v "007" ] ; fhir:display [ fhir:v "AML(megakaryoblastic) with RBM15-MKL1" ] ] [ fhir:code [ fhir:v "008" ] ; fhir:display [ fhir:v "AML with mutated NPM1" ] ] [ fhir:code [ fhir:v "009" ] ; fhir:display [ fhir:v "AML with biallelic mutation of CEBPA" ] ] [ fhir:code [ fhir:v "010" ] ; fhir:display [ fhir:v "AML with mutated FLT3/ITD" ] ] [ fhir:code [ fhir:v "011" ] ; fhir:display [ fhir:v "AML with mutated FLT3/TKD" ] ] [ fhir:code [ fhir:v "012" ] ; fhir:display [ fhir:v "AML with MLL-PTD (partial tandem duplication)" ] ] [ fhir:code [ fhir:v "013" ] ; fhir:display [ fhir:v "AML with BCR-ABL1" ] ] [ fhir:code [ fhir:v "021" ] ; fhir:display [ fhir:v "B lymphoblastic leukemia/lymphoma with BCR-ABL1" ] ] [ fhir:code [ fhir:v "022" ] ; fhir:display [ fhir:v "B-lymphoblastic leukemia/lymphoma with KMT2A-rearranged" ] ] [ fhir:code [ fhir:v "023" ] ; fhir:display [ fhir:v "B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1 (TEL-AML1)" ] ] [ fhir:code [ fhir:v "024" ] ; fhir:display [ fhir:v "B-lymphoblastic leukemia/lymphoma with IGH/IL3" ] ] [ fhir:code [ fhir:v "025" ] ; fhir:display [ fhir:v "B-lymphoblastic leukemia/lymphoma with TCF3-PBX1 (E2A-PBX1)" ] ] [ fhir:code [ fhir:v "041" ] ; fhir:display [ fhir:v "Mixed phenotype acute leukemia with BCR-ABL1" ] ] [ fhir:code [ fhir:v "042" ] ; fhir:display [ fhir:v "Mixed-phenotype acute leukemia with KMT2A-rearranged" ] ] [ fhir:code [ fhir:v "051" ] ; fhir:display [ fhir:v "Chronic myelogenous leukemia BCR-ABL1 positive" ] ] [ fhir:code [ fhir:v "052" ] ; fhir:display [ fhir:v "JAK2 V617F mutation" ] ] [ fhir:code [ fhir:v "053" ] ; fhir:display [ fhir:v "Myeloid and lymphoid neoplasms with PDGFRA rearrangement" ] ] [ fhir:code [ fhir:v "054" ] ; fhir:display [ fhir:v "Myeloid and lymphoid neoplasms with PDGFRB rearrangement" ] ] [ fhir:code [ fhir:v "055" ] ; fhir:display [ fhir:v "Myeloid and lymphoid neoplasms with FGFR1 rearrangement" ] ] [ fhir:code [ fhir:v "090" ] ; fhir:display [ fhir:v "(1) 一種異常，其他上述未列之分子檢驗異常 (2) 二種異常，其中一種非上述之分子檢驗異常 (3) 二種異常，二種皆非上述之分子檢驗異常" ] ] [ fhir:code [ fhir:v "091" ] ; fhir:display [ fhir:v "同時有兩種(含)以上上述之分子檢驗異常" ] ] [ fhir:code [ fhir:v "092" ] ; fhir:display [ fhir:v "同時有三種(含)以上分子檢驗異常 (1) 三種(含)以上異常，其中一種以上非上述之分子檢驗異常 (2)三種(含)以上異常，皆非上述之分子檢驗異常" ] ] [ fhir:code [ fhir:v "8XX" ] ; fhir:display [ fhir:v "Molecular study after chemotherapy or immunotherapy or target therapy" ] ] [ fhir:code [ fhir:v "988" ] ; fhir:display [ fhir:v "不適用。(1) ICD-O-3 M-9811-9837 (EXCEPT C42.0, 42.1, 42.4)" ] ] [ fhir:code [ fhir:v "998" ] ; fhir:display [ fhir:v "有執行分子生物學檢查，但結果無法判斷" ] ] [ fhir:code [ fhir:v "999" ] ; fhir:display [ fhir:v "(1) 病歷未記載或不詳 (2) 未執行分子生物學檢查" ] ] ) . # # -------------------------------------------------------------------------------------